



**Board of Trustees Meeting  
Thursday, December 12, 2024  
Crawford Cooley Conference Room/ZOOM**

Members Present In Person: Andy Barnes, Matt Carbone, Peter Fioretti, Anisya Fritz, David Gensler, Jim Henry, Jane Inch, Jill Kinney, Lizellen La Follette, Blair LaCorte, Afaf Meleis, Steven Read, Lew Reid, Lilian Shackelford Murray, Richard Stone, Eric Verdin

Members Present on Zoom: Jim Buzzitta, Lydia Graham, Bill Poland, Robert Rosenkranz, Jack Rowe, Theo Schwabacher, Paul Verkuil, Joon Yun

Others Present: Ana Marie Cuervo (SAB Chair), Jennifer Garrison, Remy Gross, Freda Kong, Malene Hanson, Danielle Herrerias, Meagan Moore, Lauren Newman, Robin Snyder, Brian Van Weele, Shelby Willits

**MINUTES**

**I. Call to Order**

A quorum was confirmed and the meeting began at 9:08 am.

**II. Approval of Minutes**

**(M/S/UC)** The Board of Trustees approved the September 19, 2024 Board meeting minutes.

**III. Introduction by Board Chair, Matt Carbone and Opening Comments**

Matt Carbone introduced the Buck's new CFO, Freda Kong, and emphasized the importance of attending board meetings in person.

**IV. Audit Committee Report**

David Gensler noted the Institute's audit report came back clean with no issues.

**V. Finance Committee Report**

Jim Henry presented the current budget-to-actuals report and the complete year end financials.

The Board had an open discussion on unrestricted cash and raising unrestricted funds. The Committee anticipated the Institute to be cash neutral by year end.

#### **VI. 2024 in Review & Looking Ahead to 2025 – Eric Verdin, MD, CEO & President, Professor**

Eric Verdin presented an Institute update and reviewed the accomplishments of 2024, including the Buck's Clinical Research Unit (CRU), which currently has multiple trials ongoing in various stages.

Eric Verdin also presented on what to anticipate in the new year, including Dr. Nathan Price currently building his lab and moving full-time to the Bay Area.

Eric Verdin also anticipates recruiting for a new Faculty member to replace Dr. Judy Campisi's footprint. Dr. Verdin discussed potential allies in the Trump administration as a way to foster productive connections.

#### **VII. Business of the Buck – Remy Gross, EVP, Administration**

Remy Gross presented on the administrative operations of the Buck. Remy Gross is developing department metrics to include finance, philanthropy, and business development, and cores, promoting fiscal accountability within departments.

The Institute's operating budget is tracking seasonally to the projected FY25 budget. The ARPA-H award greatly narrows shortfall risk.

Remy Gross emphasized the importance of more streamlined allowance toward breakthrough science and "Buck Funds" alignment.

Remy Gross gave an update on the four Philanthropic Initiatives:

1. Center for Human Healthspan
2. Center for Healthy Aging in Women
3. Center for Geroscience Education
4. Buck Innovation & New Discoveries

#### **VIII. "News You Can Use" by Eric Verdin, MD, CEO & President, Professor**

Eric Verdin presented the drug Ozempic and how similar GLP-1 drugs work, as well as the most common side effects and potential impacts.

#### **IX. Closing Comments**

Matt Carbone thanked Lydia Graham for her service on the Board as she will be leaving in January 2025.

The meeting adjourned at 12:17 pm.